COST-EFFECTIVENESS AND OUTCOMES GUIDELINES -- AS WELL AS DRUG PRICING -- WOULD BE OVERSEEN BY DrugPAC UNDER STARK BILL; OUTCOMES DATA TO BE COLLECTED BY AHCPR
The development of guidelines on drug cost-effectiveness and relative outcomes would be overseen by the same entity that evaluates the pricing of drugs under the alternative health care reform proposal developed by Rep. Stark (D-Calif.) that is now being marked up by his House Ways & Means/Health Subcommittee.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth